홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.1
  1. 홈
  2. /화합물

Flecainide

HCID 3356
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
54143-55-4
표준 SMILES
O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F
InChIKey
DJBNUMBKLMJRSA-UHFFFAOYSA-N
분자식
C17H20F6N2O3
평균 분자량
414.34 g/mol
단동위원소 질량
414.13781148

개요

Flecainide is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart). It has a role as an anti-arrhythmia drug. It is a member of piperidines, a monocarboxylic acid amide, an aromatic ether and an organofluorine compound. It is a conjugate base of a flecainide(1+).

이름 및 식별자

우선 이름
Flecainide
IUPAC
N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
영어명
Flecainide
분자식
C17H20F6N2O3
분자량
414.34

이름 및 동의어

flecainide54143-55-4FlecaineN-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamideFlecainidaFlecainidum(+-)-FlecainideN-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamideCCRIS 313Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-DTXSID8023054NSC-719273
이름 더 보기
Flecainide-d4Flecaniderac FlecainideFLECAINTDE BASEFlecainide USP/EP/BP(±)-Flecainide solution(±)-Flecainide solutionN-(Piperidin-2-ylmethyl)
K94FTS1806DTXCID403054CHEBI:75984THN-102 COMPONENT FLECAINIDEFlecainid IsisRefChem:56566C01BC04685-650-9

데이터베이스 식별자

CAS
54143-55-4、54143-56-5
PubChem CID
3356

물성

구조 계산 물성보충 중

XLogP
3.8
극성 표면적
59.6 Ų
수소 결합 공여자 수
2
수소 결합 수용자 수
10
회전 가능 결합 수
7
무거운 원자 수
28
형식 전하
0
복잡도
500

실험 및 물리화학적 성질

PFASPFAS -> PFAS identified in REACH Regulation EC No. 1272/2008
Drugs · 3건

Pharmaceuticals

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals -> Cardiovascular system -> Cardiac therapy

LogP · 2건

4.6

3.78

Solubility3.24e-02 g/L
Human Drugs · 2건

Breast Feeding; Lactation; Milk, Human; Antiarrhythmics

Pharmaceuticals

Melting Point228-229
Physical DescriptionSolid
Dissociation Constants · 2건

9.3

9.3

Collision Cross Section192.2 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

물리화학적 성질

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P261, P264, P270, P271, P280, P301+P317, P304+P340, P318, P319, P330, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Regulatory InformationREACH registered substance: N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide (EC: 685-650-9)
Hazard Classes and CategoriesAcute Tox. 4 (100%)

독성 정보

Treatment · 1건

Treatment of flecainide toxicity involves increasing the excretion of flecainide, blocking its effects in the heart, and (rarely) institution of cardiovascular support to avoid impending lethal arrhythmias. Modalities that have had success include administration of a beta-sympathomimetic agent, and administration of a sodium load (often in the form of hypertonic sodium bicarbonate). Placing the individual on cardiopulmonary bypass support may be necessary in order to temporarily obviate the need for a beating heart and to increase blood flow to the liver. (L1129)

Health Effects · 1건

Signs of flecainide toxicity include marked prolongation of the PR interval and widening of the QRS duration on the surface ECG. There may be signs and symptoms attributable to overt heart failure secondary to sudden decreased myocardial contractility (L1129).

Hepatotoxicity · 1건

In clinical trials, flecainide was associated with a low rate of serum aminotransferase and alkaline phosphatase elevations. Despite wide scale use, flecainide has only rarely been linked to cases of clinically apparent liver injury. The typical presentation is with a cholestatic hepatitis arising within 1 to 6 weeks of starting flecainide. In addition, instances of acute hepatic injury arising within 1 to 3 days of starting flecainide with marked, but short lived elevations in serum aminotransferase levels and minimal increases in alkaline phosphatase have been published, but may actually represent acute worsening of congestive heart failure and ischemic hepatitis due to the proarrhythmic effects of flecainide. In all instances, the liver injury was self limited. Immunoallergic and autoimmune features were not present.

화학 및 산업

약리 정보

ATC Code · 3건

C01BC04

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingFlecainide is 40% bound to protein in serum, mainly to alpha-1-acid glycoprotein and minorly to serum albumin.
Pharmacodynamics · 1건

Flecainide inhibits the action of sodium and potassium ion channels in the heart, raising the threshold for depolarization and correcting arrhythmias. Flecainide has a long duration of action, allowing for once daily dosing. The therapeutic index is narrow. Patients should not take this medication if there is already structural heart disease or left ventricular systolic dysfunction.

Mechanism of Action · 1건

Flecainide blocks fast inward sodium channels and slowly unbinds during diastole, prolonging the refractory period of the heart. This blockade also shortens the duration of action potentials through the Purkinjie fibers. Flecainide also prevents delayed rectifier potassium channels from opening, lengthening the action potential through ventricular and atrial muscle fibers. Finally, flecainide also blocks ryanodine receptor opening, reducing calcium release from sarcoplasmic reticulum, which reduces depolarization of cells.

Biological Half-Life · 1건

In healthy subjects, intravenous flecainide has an average half life of 13 hours for a single dose and 16 hours for multiple oral doses. In patients with a ventricular premature complex, flecainide has a half life of 20 hours. The half life of meta-O-dealkylated flecainide, a major metabolite of flecainide, is 12.6h.

Metabolism/Metabolites · 2건

Flecainide is mainly metabolized to meta-O-dealkylated flecainide or the meta-O-dealkylated lactam of flecainide. Meta-O-dealkylated flecainide has 20% the activity of flecainide. Both of these metabolites are generally detected as glucuronide or sulfate conjugates. Flecainide’s metabolism involves the action of CYP2D6 and CYP1A2.

Hepatic. Flecainide does not undergo any consequential presystemic biotransformation. The two major urinary metabolites are meta-O-dealkylated flecainide (active, but about one-fifth as potent) and the meta-O-dealkylated lactam of flecainide (non-active metabolite). The absoprtion is nearly complete following oral administration. Hepatic. Flecainide does not undergo any consequential presystemic biotransformation. The two major urinary metabolites are meta-O-dealkylated flecainide (active, but about one-fifth as potent) and the meta-O-dealkylated lactam of flecainide (non-active metabolite). Route of Elimination: In healthy subjects, about 30% of a single oral dose (range, 10 to 50%) is excreted in urine as unchanged drug. Several minor metabolites (3% of the dose or less) are also found in urine; only 5% of an oral dose is excreted in feces. In patients, free (unconjugated) plasma levels of the two major metabolites are very low (less than 0.05 ug/mL). Half Life: 20 hours (range 12-27 hours)

관련 반응

14건
반응 기록 만들기
HRID 460428 반응식
HRID 460428생성물로uspto-grants-2007_03
HRID 460429 반응식
HRID 460429반응물로uspto-grants-2007_03
HRID 838420 반응식
HRID 838420생성물로Test data from https://doi.org/10.1039/C8SC04228D
HRID 959705 반응식
HRID 959705반응물로Validation data from https://doi.org/10.1039/C8SC04228D
HRID 1138736 반응식
HRID 1138736반응물로Training data from https://doi.org/10.1039/C8SC04228D (7/10)
HRID 1359120 반응식
HRID 1359120반응물로uspto-grants-2003_07
HRID 1359121 반응식
HRID 1359121생성물로uspto-grants-2003_07
HRID 2290621 반응식
HRID 2290621반응물로uspto-grants-1986_10
이전1 / 2 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
DTXSID
DTXSID8023054
ChEMBL
CHEMBL652
ChEBI
CHEBI:75984
UNII
K94FTS1806
EC Number
685-650-9、923-247-4
Nikkaji
J12.413C、J399.064H、J399.065F
녹는점
105 · 105-1070C
끓는 점
434.9 · 434.9±45.0 °C(Predicted)
밀도
1.286 · 1.286±0.06 g/cm3(Predicted)
인화점
9 ℃ · 9℃
저장 조건
Keep in dark place,Inert atmosphere,Room temperature
용해도
클로로포름(약간 용해됨), 메탄올(약간 용해됨)
물리적 상태
고체
산도 계수 (pKa)
9.3 · pKa 9.3 (Uncertain)
색상
흰색에서 황백색까지
BCS Class
1 or · 1 or 2
주요 응용
임상 시험
InChI
1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)
InChIKey
DJBNUMBKLMJRSA-UHFFFAOYSA-N
SMILES
O=C(NCC1CCCCN1)C2=CC(OCC(F)(F)F)=CC=C2OCC(F)(F)F
NIST
2 · Benzamide, n-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-(54143-55-4)

화학적 성질

White Crystalline Powder

Adverse EffectsCardiac Toxicity
Exposure RoutesIngestion (MSDS, A308). Nearly complete following oral administration.
Toxicity Summary · 2건

Signs and Symptoms of Overdose

Flecainide acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Flecainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole.

Signs and Symptoms · 1건

Symptoms of overdose include nausea and vomiting, convulsions, hypotension, bradycardia, syncope, extreme widening of the QRS complex, widening of the QT interval, widening of the PR interval, ventricular tachycardia, AV nodal block, asystole, bundle branch block, cardiac failure, and cardiac arrest.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 5건

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

flecainide

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: 50-498 mg/kg (Oral, Rat) (A308)

안전 데이터

wgk
1
ridadr
3249
risk_code
11-23/24/25-39/23/24/25
hazard_code
F,T
safety_code
7-16-36/37-45
포장분류
III
위험 등급
6.1(b)
Hazard Classifications
Acute Tox. 3 DermalAcute Tox. 3 InhalationAcute Tox. 3 OralFlam. Liq. 2STOT SE 1
스토리지 클래스
3 - Flammable liquids
FDA Pharmacological Classification · 4건

K94FTS1806

FLECAINIDE

Established Pharmacologic Class [EPC] - Antiarrhythmic

Flecainide is an Antiarrhythmic.

MeSH Pharmacological Classification · 2건

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS.

Absorption, Distribution and Excretion · 4건

Oral flecainide has a Tmax of 3-4h and a bioavialability of 90%. Taking flecainide with food or aluminum hydroxide antacids do not significantly affect the absorption of flecainide.

Approximately 86% of a single oral dose is eliminated in the urine, with 42% as unchanged flecainide and 14% as meta-O-dealkylated flecainide, a similar amount of the meta-O-dealkylated lactam of flecainide, approximately 3% as an unidentified acid metabolite, and <1% as 2 other unknown metabolites. 5% is eliminated in the feces.

The average volume of distribution in 8 male subjects is 5.0-13.4L/kg.

The average clearance of intravenous flecainide is 4.6-12.1mL/min/kg in 8 male subjects. For oral flecainide, the clearance was 4-20mL/min/kg.

Cellular LocationsMembrane
Metabolite PathwaysFlecainide Action Pathway

용도 및 제조

Uses · 2건

Use (kg; approx.) in Germany (2009): >2500

Flecainide is is a class Ic antiarrhythmic agent and as such, it is used for the prevention of paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disablin (A308).

Use ClassificationPharmaceuticals

응용 분야

개요From the chemical point, flecainide is an analog of procainamide, to which a 2.2.2-trifluoroethoxyl group was added at C2 and C3 of the benzene ring, and a diaminoethyl side chain is ended in the piperidine ring.

용도Flecainide, as with other local anesthetics, is used for naturally occurring ventricular arrhythmia.

상·하류 제품 정보

상류 원료

2-(아미노메틸)피페리딘Desiccant2,5-다이하이드록시벤조익애씨드피콜리아민황산마그네슘염산2,5-비스(2,2,2-트리플루오로에톡시)벤조산2,2,2-트리플루오로에틸2,5-BIS(2,2,2-트리플루오로에톡시)벤조에이트METHYL 2,5-BIS(2,2,2-TRIFLUOROETHOXY)BENZOATE
추가 설명 · 1건

정의ChEBI: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prev nt and treat tachyarrhythmia (abnormal fast rhythm of the heart).